Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Cancer research - 1 Jan 2013

Janku Filip, Wheler Jennifer J, Naing Aung, Falchook Gerald S, Hong David S, Stepanek Vanda M, Fu Siqing, Piha-Paul Sarina A, Lee J Jack, Luthra Rajyalakshmi, Tsimberidou Apostolia M, Kurzrock Razelle

Abstract excerpt

PIK3CA mutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy were analyzed for PIK3CA and, if possible, KRAS mutations. Patients with PIK3CA mutations were treated, whenever possible, with agents targeting the PI3K/AKT/mTOR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Resistance, Neoplasm

Share to Kaplan-Meier Estimate

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23066039
DOI: 10.1158/0008-5472.CAN-12-1726
PMCID: PMC3537862

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.PMID 23066039Read ↗

PIK3CA mutations in advanced cancers: characteristics and outcomes.Semantic proximity Read ↗

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.Semantic proximity Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Semantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Semantic proximity Read ↗

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted TherapeuticsSemantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.Semantic proximity Read ↗

PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.Semantic proximity Read ↗

Genomic Determinants of PI3K Pathway Inhibitor Response in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.